CA3175945A1 - Compositions and methods for treating and preventing lung disease - Google Patents

Compositions and methods for treating and preventing lung disease

Info

Publication number
CA3175945A1
CA3175945A1 CA3175945A CA3175945A CA3175945A1 CA 3175945 A1 CA3175945 A1 CA 3175945A1 CA 3175945 A CA3175945 A CA 3175945A CA 3175945 A CA3175945 A CA 3175945A CA 3175945 A1 CA3175945 A1 CA 3175945A1
Authority
CA
Canada
Prior art keywords
seq
peptide
asthma
purified peptide
therapeutic agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3175945A
Other languages
English (en)
French (fr)
Inventor
Julie LEDFORD
Monica KRAFT
Josef Vagner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Raesedo LLC
University of Arizona
Original Assignee
Raesedo LLC
University of Arizona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/409,642 external-priority patent/US20210379141A1/en
Application filed by Raesedo LLC, University of Arizona filed Critical Raesedo LLC
Priority claimed from PCT/US2022/075356 external-priority patent/WO2023028491A1/en
Publication of CA3175945A1 publication Critical patent/CA3175945A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/785—Alveolar surfactant peptides; Pulmonary surfactant peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3175945A 2021-08-23 2022-08-23 Compositions and methods for treating and preventing lung disease Pending CA3175945A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17/409,642 2021-08-23
US17/409,642 US20210379141A1 (en) 2016-04-11 2021-08-23 Compositions and methods for treating and preventing lung disease
PCT/US2022/075356 WO2023028491A1 (en) 2021-08-23 2022-08-23 Compositions and methods for treating and preventing lung disease

Publications (1)

Publication Number Publication Date
CA3175945A1 true CA3175945A1 (en) 2023-02-23

Family

ID=85278728

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3175945A Pending CA3175945A1 (en) 2021-08-23 2022-08-23 Compositions and methods for treating and preventing lung disease

Country Status (6)

Country Link
EP (1) EP4392052A4 (https=)
JP (1) JP2024532412A (https=)
KR (1) KR20240052799A (https=)
CN (1) CN118076372A (https=)
AU (1) AU2022332283A1 (https=)
CA (1) CA3175945A1 (https=)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017180546A1 (en) * 2016-04-11 2017-10-19 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating and preventing lung disease
EP4132470A4 (en) * 2020-04-08 2023-11-08 Arizona Board of Regents on behalf of the University of Arizona COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF LUNG DISEASES

Also Published As

Publication number Publication date
AU2022332283A1 (en) 2024-03-07
EP4392052A1 (en) 2024-07-03
CN118076372A (zh) 2024-05-24
JP2024532412A (ja) 2024-09-05
EP4392052A4 (en) 2025-07-23
KR20240052799A (ko) 2024-04-23

Similar Documents

Publication Publication Date Title
US11110152B2 (en) Compositions and methods for treating and preventing lung disease
ES2979287T3 (es) Tratamiento de infección respiratoria
US20230190861A1 (en) Peptide therapeutics for acute and chronic airway and alveolar diseases
BR112021004420A2 (pt) formulação em pó seco de peptídeos de caveolina-1 e métodos de uso dos mesmos
CN103200955A (zh) 包含肽和病毒神经氨酸酶抑制剂的组合物
US20240269242A1 (en) Compositions and methods for treating and preventing lung disease
US20230135877A1 (en) Compositions and methods for treating and preventing lung disease
CA3175945A1 (en) Compositions and methods for treating and preventing lung disease
WO2023028491A1 (en) Compositions and methods for treating and preventing lung disease
US20210379141A1 (en) Compositions and methods for treating and preventing lung disease
JP2012505207A (ja) 慢性閉塞性肺疾患の予防用または治療用の薬剤組成物
US20250262273A1 (en) Modified caveolin-1 peptides for the treatment of chronic kidney disease
RU2737799C1 (ru) Ингаляционный гексапептид для лечения респираторных заболеваний, связанных с интерлейкином-6
US12551533B2 (en) Intranasal neuropeptides for use in stress-related impairments
US20250144205A1 (en) Compositions and methods for treating infectious diseases
US20250059268A1 (en) Compositions and methods for treatment of chronic lung diseases
EP3113786B1 (en) Attenuation of intrapulmonary inflammation
WO2021211006A1 (en) Inhaled hexapeptide for treating interleukin-6 related respiratory diseases

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250815

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250815

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20251014

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251015